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Abstract 
The multikinase inhibitors Sunitinib and Sorafenib not only inhibit angiogenesis and 
tumor growth, but also have the potential of interacting with the function of the immune 
system. 
Presently available data seem to suggest that Sorafenib may exert immune suppressive 
effects, whilst the effects of Sunitinib are not so clear, being immune stimulatory in the 
vast majority – but not all – the studies reported. 
Trials of combination of these multikinase inhibitors with different types of immune 
manipulation – and cellular therapies in particular – should be rationally designed taking 
into account all these complex effects, which ultimately deserve further insights. 
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INTRODUCTION 
Renal cell carcinoma (RCC) is the most common 
malignancy of the kidney and accounts for approxi-
mately  3%  of  all  adult  malignancies  and  2%  of  all 
deaths from neoplasms. 
The only treatment with curative intent for pa-
tients with localized RCC is radical surgical resection 
of  the  tumor;  however,  20-30%  of  patients  present 
with synchronous metastases at diagnosis, while up 
to 30-35% of more patients, initially radically resected, 
will eventually develop metastases over time (1). 
Overexpression  of  P-glycoprotein  (P-gp)  en-
coded by the multidrug resistance 1 (MDR1) gene or 
multidrug  resistance-associated  protein  (MRP)  (or 
both), as well as decreased expression of DNA topoi-
somerase II is responsible for expression of the mul-
tidrug resistance (MDR) phenotype in the vast major-
ity of RCCs (2), so that conventional chemotherapy is 
largely  ineffective  in  this  tumor,  which  is  also  re-
sistant to radiations, radiotherapy being only useful 
for palliation of bone or cerebral metastases (3). 
The  above  peculiarities  of  this  neoplasm,  to-
gether with the recognition of the frequent presence of 
several immunologic dysfunctions in RCC (4), even in 
the absence of metastases (5), have rendered this tu-
mor a privileged field for the development and clini-
cal application of immunotherapy. 
Indeed, until 2005, immunotherapy has been the 
treatment of choice for advanced RCC patients, even 
though the generic term ‘immunotherapy’ comprises 
a vast array of different therapeutic approaches (in-
cluding  cellular  therapies),  unfortunately  too  often 
evaluated only within small, non-randomized, phase 
II studies. 
Starting from 2005 onward, six molecularly tar-
geted drugs (i.e., the three multikinase inhibitors So-
rafenib,  Sunitinib  and  Pazopanib,  the  anti-VEGF 
monoclonal antibody Bevacizumab – used in combi-
nation with Interferon- – and the two mTOR inhibi-
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tors  Temsirolimus  and  Everolimus),  proved  to  be 
able,  within  large  randomized  trials,  to  change  the 
natural history of advanced RCC (6-11), thus estab-
lishing new standards for both first- and even subse-
quent-lines of treatment (Table 1). 
Table 1. A proposed algorithm of treatment for advanced RCC (in bold are reported the options supported by at least 
one randomized, controlled, phase III, clinical trial).  
1st line     
  MSKCC* good and intermediate risk  Sunitinib 
Bevacizumab + Interferon-a 
Pazopanib 
Sorafenib (selected patients) 
High-dose i.v. IL-2 (?) 
  MSKCC* poor risk  Temsirolimus 
Sunitinib 
2nd line     
  Post-cytokines  Sorafenib 
Pazopanib 
Sunitinib 
  Post-one multi-kinase inhibitor  Everolimus 
a second multi-kinase inhibitor 
3rd line     
  Post-two multi-kinase inhibitors  Everolimus 
  Post-Everolimus  Clinical trial 
Sorafenib (?) 
*MSKCC (or Motzer’s) score takes into consideration the following parameters: ECOG Performance Status, hemoglobin levels, LHD levels, 
corrected calcium levels, and prior history of nephrectomy – or interval between diagnosis and treatment start; 0 risk factors = good risk; 1-2 
risk factors = intermediate risk; >2 risk factors = poor risk. 
 
 
Despite such an abundance of active agents (a 
scenario that has been brilliantly defined as the ‘em-
barassment of the riches’) (12), cure is still out of our 
sights, progression-free survival (PFS) for almost all 
these agents rarely exceeding eleven months. 
To further improve the results obtained so far, 
the combination of molecularly targeted agents with 
immunotherapy is considered as a promising inves-
tigational therapeutic approach, even though – to date 
– only Interferon- and Interleukin-2 (IL-2) have been 
successfully combined with the multikinase inhibitor 
Sorafenib (13-17).   
However, it is important to highlight that all the 
above molecularly targeted drugs inhibit different key 
signal transduction pathways that, not only are im-
plicated  in  the  complex  processes  of  angiogenesis, 
tumor growth, metabolism and survival, but also play 
many other physiological roles. 
In particular, if these pathways are relevant also 
for the immune system – and they indeed are relevant 
–  what  does  really  happen  from  an  immunological 
viewpoint  when  these  pathways  are  pharmacologi-
cally inhibited? These actions may further impair the 
already  compromised  antitumor  activity  of  the  im-
mune system? And, more than any other issue, could 
we exploit all these informations to more rationally 
design the next generation of clinical trials, including 
both molecularly targeted agents and immunotherapy 
(including cellular therapies)? (18) 
IMMUNOLOGICAL EFFECTS OF SORAFENIB 
TOSYLATE 
Sorafenib  tosylate  (a.k.a.  BAY  43-9006, 
Nexavar™) is an oral, small molecule inhibitor of sev-
eral tyrosine protein kinases (e.g., VEGFR-2 and -3, 
PDGFR-, Flt-3 and c-Kit), heavily involved in tumor 
angiogenesis, as well as of the serine-threonine kinase 
Raf,  a  key  protein  within  the  RAF/MEK/ERK  sig-
naling pathway (19). 
Sorafenib and Dendritic cells (DCs) 
An elegant paper addressed the different effects 
of Sorafenib (and Sunitinib) on DCs phenotype and 
function (20). 
Exposure  to  pharmacologic  concentrations  of 
Sorafenib  induced,  on  myeloid-derived  DCs,  a  pro-
nounced down-regulation of CD1a, i.e., a glycopro-
tein  structurally  related  to  the  Major  Histocompati-
bility Complex (MHC), of the co-stimulatory molecule 
B7.2 (or CD86), as well as of the Dendritic Cell Specific 
Intercellular  adhesion  molecule-3-Grabbing 
Non-integrin  (DC-SIGN  or  CD209),  a  C-type  lectin 
that mediates the adhesion of DCs to T cells by stabi-
lizing  the  DC/T  cells’  contact  zone  (20).  In  vivo, Journal of Cancer 2011, 2 
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treatment  with  Sorafenib  significantly  reduced  the 
induction of antigen-specific T cells in C57BL/6 mice 
immunized with the OVA257-264 peptide (20), a class I 
(Kb)-restricted peptide epitope of OVA, an octameric 
peptide  from  ovalbumin  presented  by  the  class  I 
MHC molecule, H-2Kb. 
Furthermore,  Sorafenib-treated  DCs  displayed 
impaired migratory capacity, through a reduced ex-
pression  of  the  chemokine-CC  motif  receptor  7 
(CCR7), the receptor for CCL19/MIP-3, a system that 
regulates the migration of mature DCs from periph-
eral  tissues  to  local  lymph  nodes  across  a 
CCL19/MIP-3 gradient (21). 
Pre-treatment with Sorafenib reduced the capac-
ity of TLR4 ligand-activated antigen-presenting cells 
(APCs)  to  stimulate  lymphocyte  proliferation,  and 
lowered DC cytokine secretion (20). 
Sorafenib (but not Sunitinib) induced apoptosis 
of DCs, and attenuated primary CD8+ T-cell response 
in a mouse model in vivo (20). 
As  a  whole,  Sorafenib  –  but  not  Sunitinib  – 
proved  able  to  inhibit  DCs’  function,  cytokine  pro-
duction, and  ability  to  migrate and  stimulate  T-cell 
responses (20). Notably, all these immunosuppressive 
effect  were  mediated  via  Sorafenib-induced  inhibi-
tion, not only of the MAPK pathway, but also of the 
PI3K and NFB signaling pathways (20), a relatively 
unexpected finding since Sorafenib is not known to 
directly inhibit the two latter pathways. 
Sorafenib, Natural Killer (NK) cells and 
CD4
+/CD25
high T-cells 
In  another  experimental  study  it  has  been 
demonstrated that cytokine production and antitumor 
cytotoxicity  of  resting  and  IL-2-activated  peripheral 
blood mononuclear cells (PBMCs) were inhibited by 
pharmacological  concentrations  of  Sorafenib;  fur-
thermore,  pharmacological  concentrations  of  Soraf-
enib  proved  able  to  impair  granule  mobilization  of 
NK cells among PBMCs, and inhibit NK cells reactiv-
ity (22). Once again, these immunosuppressive effects 
were  mediated  via  Sorafenib-induced  inhibition  of 
both  the  MAPK  pathway,  as  well  as  of  the  PI3K 
pathway (22). 
Sorafenib proved also able to induce apoptosis of 
CD4+/CD25high T cells if administered prior to anti-
genic stimulation, whilst this effect was prevented by 
the administration of IL-2 (23). 
Sorafenib tosylate and the immune system: 
conclusions 
From the above evidence, it is clear that Soraf-
enib has potentially immunosuppressive effects (Fig-
ure 1). 
 
Figure 1 – The putative immune-suppressive effects of Sorafenib are exerted on Dendritic Cells (DCs)/Antigen Pre-
senting Cells (APCs) and Natural Killer (NK) cells. Journal of Cancer 2011, 2 
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At this point, we should ask ourselves at least a 
couple of questions: since Sorafenib is highly active, in 
man, against several tumors (not only kidney cancer, 
but also HCC and thyroid cancer) (24-26), which – if 
any – is the real impact of such drug-induced immune 
suppression? And then, is it really possible that a drug 
such  as  Sorafenib,  we  suppose  to  know  quite  well, 
could really interfere with pathways such as the PI3K, 
or the NFB ones, as it appears from the previously 
cited experimental papers? 
To date, the latter question has no clear-cut an-
swers,  more  biological  studies  being  needed  to  ad-
dress this point. 
As far as the first answer, it is clear that the pu-
tative  immune  suppressant  properties  of  Sorafenib 
have no impact at all on its anti-angiogenic and anti-
tumor activity; however, these immunological effects 
should be taken into account when (and if) Sorafenib 
will  be  administered  together  with  other  forms  of 
immunotherapy.  
IMMUNOLOGICAL EFFECTS OF SUNITINIB 
MALATE 
Sunitinib malate (a.k.a. SU011248, Sutent™) is an 
oral, small molecule inhibitor of several tyrosine pro-
tein  kinases  involved  in  tumor  angiogenesis  (e.g., 
VEGFR1 through -3, PDGFR- and -, Flt-3, CSF-1) 
(27). 
Sunitinib malate: anti-immune suppressive ef-
fects 
Sunitinib  was  the  first  multikinase  inhibitor 
whose  immunological  effects  have  been  specifically 
studied in vivo. 
After a single cycle of Sunitinb an increase in the 
percentage of Interferon- producing T-cells, a reduc-
tion in the percentage of IL-4 producing T-cells, and a 
diminished  type-2  bias,  was  observed  (28);  further-
more,  immune  suppressant  CD4+/CD25high/Foxp3+ 
regulatory T-cells (Treg) proved to be down-regulated 
after Sunitinib treatment (28). 
CD33+/HLA-DR-  and  CD15+/CD14-  Mye-
loid-Derived  Suppressor  Cells  (MDSC),  which  are 
usually elevated in RCC patients (29), declined in re-
sponse to Sunitinib treatment, which suppresses bone 
marrow production of MDSC, while enhancing lym-
phoid cell proliferation (30).  
Differently from Sorafenib, Sunitinib do not af-
fect DCs or NK cells phenotype and function (20,22); 
on the contrary, Sunitinib reduces the expression of 
immune  suppressive  cytokines  and  co-stimulatory 
molecules,  such  as  IL-10,  Foxp3,  PD-1,  CTLA4  and 
BAFF (B lymphocyte-activating factor), in tumor in-
filtrating  lymphocytes  (TILs)  from  Sunitinib-treated 
mice (31). More importantly, the expression of nega-
tive costimulatory molecules CTLA4 and PD-1 in both 
CD4+  and  CD8+  T  cells,  and  PDL-1  expression  on 
MDSC and plasmacytoid DCs, was also significantly 
decreased by Sunitinib treatment (31). 
Furthermore, T cells from Sunitinib-treated mice 
exhibited stronger cytotoxic activity, and increased 2.5 
fold the number of CD4+ and CD8+ cells within the 
TILs  population  (31).  Finally,  Treg  and  MDSC  are 
reduced by Sunitinib treatment in this mouse model 
(31). 
Finally, Sunitinib restores DC number and nor-
malizes myeloid lineage distribution in RCC patients; 
indeed, subsequent to Sunitinib treatment, an increase 
to high levels of myeloid DCs subset frequencies rela-
tive  to  other  myeloid  subsets,  was  specifically  ob-
served  in  patients  experiencing  tumor  regression; 
moreover,  high  CD1c/BDCA-1+  myeloid  DC  fre-
quencies  were  predictive  for  tumor  regression  and 
improved PFS (32). 
Sunitinib: fellow or foe? 
At  this  point,  the  whole picture  appears  to  be 
clear: Sunitinib enhances antitumor immunity, while 
Sorafenib has immunosuppressive properties, isn’t it? 
Not really. 
Indeed, differently from what has been reported 
above, another recent study suggested that Sunitinib 
may also have immune suppressive effects. 
In this study, Sunitinib proved able to inhibit the 
proliferation of primary human T cells from normal 
healthy  volunteers  as  well  as  from  RCC  and  other 
cancer  patients,  an  inhibition  that  was  recoverable 
after drug withdrawal (33). In addition, Sunitinib led 
to accumulation in G0/G1 phase of the cell cycle, in-
hibition of cytokine production, down-regulation of 
activation  markers  expression,  and  blockade  of 
Zap-70 signaling in the T cells (33). 
CONCLUSIONS 
A  relevant  body  of  evidence  suggests  that  the 
multikinase  inhibitors  Sunitinib  and  Sorafenib  may 
heavily impact on the immune system. 
This is not strange, since the signaling pathways 
inhibited by these drugs are relevant also for the im-
mune  system.  For  example,  the  Mitogen-Activated 
Protein Kinase (MAPK) pathway is necessary for the 
positive selection (but not negative selection) of im-
mature, double-positive, thymocytes (34). 
Furthermore, circulating VEGF, which may in-
crease  after  multikinase  inhibitor  treatment  (35), 
proved able to inhibit DCs; indeed, the ability of ma-
ture  DCs  to  stimulate  allogeneic  T  cell  was Journal of Cancer 2011, 2 
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dose-dependently inhibited by the addition of VEGF 
in an experimental system (36). 
As a whole, presently available evidence seems 
to  suggest  that  the  multikinase  inhibitor  Sorafenib 
may exert immune suppressive effects, whilst the ef-
fects  of  Sunitinib  are  not  so  clear,  being  immune 
stimulatory  in  the  vast  majority  –  but  not  all  –  the 
studies reported. 
For years immunotherapy was the only available 
treatment  for  advanced  RCC  (37),  but  the  develop-
ment of molecularly targeted agents relegated it to a 
corner;  among  different  immune  therapeutic  ap-
proaches,  cellular  therapies  held  particular  promise 
for  the treatment of advanced RCC, since  the  early 
demonstration  that  non-myeloablative  allogeneic 
stem-cell transplantation was able to induce sustained 
regression of metastatic RCC, and even cure a small 
percentage of these patients (38). This effect was as-
sociated  with  the  recognition  of  a  peptide  (i.e., 
CT-RCC-1) by RCC-specific CD8+ T cells; the genes 
encoding this antigen were found to be derived from 
human  endogenous  retrovirus  type  E  (HERV)  and 
were expressed in RCC cell lines and fresh RCC tissue 
but not in normal kidney or other tissues (39), a find-
ing that opens the field to further research on the role 
of viruses in the processes of carcinogenesis (40). 
Despite  the  fact  that,  differently  from  cellular 
therapy, molecularly targeted agents do not allow to 
cure any of these patients, it is clear that their absolute 
benefit (i.e., a disease control rate in the range of 75 to 
80%)  makes  them  the  treatment  of  choice  for  ad-
vanced RCC. 
However, a combination of these novel agents 
with cellular therapy makes sense and deserve future 
studies. 
But any future combination between multikinase 
inhibitors with immunotherapy as a whole (and cel-
lular therapy, in particular) should be rationally de-
signed  taking  into  account  all  the  above  complex 
immunological  effects  of  the  latter  drugs,  effects 
which ultimately deserve further insights. 
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